FREEMAN SCOTT M 4
4 · ONYX PHARMACEUTICALS INC · Filed Apr 9, 2004
Insider Transaction Report
Form 4
FREEMAN SCOTT M
VP, Clinical Research
Transactions
- Sale
Common Stock
2004-04-08$43.57/sh−3,243$141,298→ 4,346 total - Exercise/Conversion
Stock Option (Right to Buy)
2004-04-08−5,000→ 10,000 totalExercise: $4.00From: 2003-01-22Exp: 2012-07-21→ Common Stock (5,000 underlying) - Sale
Common Stock
2004-04-08$43.63/sh−300$13,089→ 8,814 total - Sale
Common Stock
2004-04-08$43.58/sh−232$10,111→ 4,114 total - Exercise/Conversion
Common Stock
2004-04-08$4.00/sh+5,000$20,000→ 9,114 total - Sale
Common Stock
2004-04-08$43.60/sh−1,125$49,050→ 7,689 total - Sale
Common Stock
2004-04-08$43.61/sh−100$4,361→ 7,589 total
Footnotes (1)
- [F1]The shares subject to the option become exercisable at a rate of 12.5% on the date 6 months after the date of grant and in equal monthly installments thereafter for 42 months.